Good
Mostly Aligned
Patient Risk:
Low
Summary
Only one substantive drug-label claim (fixed-dose combination of sofosbuvir/velpatasvir) is directly supported by the provided label excerpt; the remaining claims concern patent/legal/market-expiration topics that are not addressed in the available prescribing-information sections.
Category Scores
Accurate Statements
Epclusa is a sofosbuvir/velpatasvir combination.
Supported by label excerpt 12.1: EPCLUSA is a fixed-dose combination of sofosbuvir and velpatasvir.
Unsupported Statements
Patent expiry depends on which exact patent(s) are being counted and whether you mean primary patent term, adjusted term, or additional exclusivity.
Not addressed in the provided prescribing-information sections.
For branded hepatitis C combinations like Epclusa, controlling dates typically come from composition-of-matter patents covering the drug substances and their fixed-dose combination.
Not addressed in the provided prescribing-information sections.
For branded hepatitis C combinations like Epclusa, controlling dates typically come from method-of-treatment patents (how the drug is used).
Not addressed in the provided prescribing-information sections.
Patent term adjustments or extensions tied to regulatory review can affect controlling dates for Epclusa.
Not addressed in the provided prescribing-information sections.
Related patents can extend market protection even if some earlier patents expire for branded hepatitis C combinations like Epclusa.
Not addressed in the provided prescribing-information sections.
Patent expiry does not always equal immediate generic entry.
Not addressed in the provided prescribing-information sections.
Ongoing patent litigation can delay generic launch if a generic files a challenge.
Not addressed in the provided prescribing-information sections.
Additional listed patents that block approval or delay market entry can delay generic launch.
Not addressed in the provided prescribing-information sections.
Practical regulatory/market readiness timelines can delay generic launch.
Not addressed in the provided prescribing-information sections.
Different sites may report different “expiration” dates because they may show the earliest vs. latest patent expiry.
Not addressed in the provided prescribing-information sections.
Different sites may report different “expiration” dates because they may show the primary patent term vs. adjusted/extended dates.
Not addressed in the provided prescribing-information sections.
Different sites may report different “expiration” dates because they may mix up patent protection vs. regulatory exclusivity.
Not addressed in the provided prescribing-information sections.
Biosimilars are for biologics.
Not addressed in the provided prescribing-information sections.
Generic small-molecule competition is the relevant pathway after patent protection ends for Epclusa.
Not addressed in the provided prescribing-information sections.
Contradictions
Important Omissions
No label-based omissions assessed because the claims evaluated are primarily about patent/legal and market-expiration topics, and the provided label excerpts do not cover such topics.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No dosing, contraindication, warnings, drug-interaction, or safety-treatment guidance was provided in the evaluated claims; the supported content is limited to product composition, while other content is non-label legal/market discussion.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Most claims are not supported by the provided FDA prescribing-information excerpts (they address patent/legal and market-expiration considerations not present in the label).
Suggested Improvement
Limit statements to what is actually described in the prescribing information (e.g., composition and indications). Avoid adding patent/market exclusivity timelines or generic/biosimilar pathway assertions unless they are explicitly covered in the label.